Literature DB >> 263243

Antitumor agents--dose response curve clinical and experimental considerations.

E Frei.   

Abstract

Mesh：

Substances：

Year:  1979        PMID： 263243

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


× No keyword cloud information.
  4 in total

1.  High-dose nitrogen mustard (HN2) with autologous nonfrozen bone marrow transplantation in advanced malignant melanoma. A phase I trial.

Authors:  D W Hartmann; W A Robinson; N J Morton; A Mangalik; L M Glode
Journal:  Blut       Date:  1981-04

2.  Phase II trial of intravenous melphalan in advanced colorectal carcinoma.

Authors:  D F Moore; R Pazdur; J L Abbruzzese
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.

Authors:  W P Steward; J H Scarffe; L Y Dirix; J Chang; J A Radford; E Bonnem; D Crowther
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

4.  High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.

Authors:  S A Gomm; N Thatcher; A Cuthbert; J Chang; H Burmester; P Hall; K B Carroll
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.